Conserved HBV and HCV sequences useful for gene silencing

Details for Australian Patent Application No. 2012202085 (hide)

Owner Alnylam Pharmaceuticals, Inc.

Inventors Pachuk, Catherine; Satishchandran, Chandrasekhar; Zurawski Jr., Vincent; Mintz, Liat

Agent Allens Arthur Robinson

Pub. Number AU-A-2012202085

Parent 2005319306

Filing date 11 April 2012

Wipo publication date 3 May 2012

International Classifications

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

26 April 2012 Complete Application Filed

3 May 2012 Application Open to Public Inspection

  Published as AU-A-2012202085

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012202086-Container for packaging filling materials and method for processing a web material

2012202084-Allergen peptide fragments and use thereof